RELMADA THERAPEUTICS, INC. Increase (Decrease) in Derivative Liabilities
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Derivative Liabilities of $54.63 thousand for the 12-month period ending 2019-06-30, per its 10-K filed 2021-03-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2021-03-24
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2018-12-31 was -$263.90K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2018-09-30 was $318.54K, a 5486.48% increase year-over-year.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2018-06-30 was $789.44K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for the quarter ending 2018-03-31 was $254.86K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2019 was $54.63K, a 92.29% decline from fiscal 2018.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2018 was $708.90K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2017 was -$716.65K.
- RELMADA THERAPEUTICS, INC. increase (decrease) in derivative liabilities for fiscal 2016 was -$13.11M, a 453.31% decline from fiscal 2015.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month | Increase (Decrease) in Derivative Liabilities 115 month | Increase (Decrease) in Derivative Liabilities 118 month |
|---|---|---|---|---|---|---|
| 2019-06-30 | $54.63K 10-K · filed 2021-03-24 | |||||
| 2018-12-31 | -$263.90K derived: 10-KT 6 month − 10-Q 3 month · filed 2020-03-26 | $54.64K 10-KT · filed 2020-03-26 | $844.08K derived: sum of 3 quarters · filed 2020-03-26 | $1.10M derived: sum of 4 quarters · filed 2020-03-26 | ||
| 2018-09-30 | $318.54K 10-Q · filed 2018-11-13 | $1.11M derived: sum of 2 quarters · filed 2020-03-26 | $1.36M derived: sum of 3 quarters · filed 2020-03-26 | $1.02M derived: sum of 4 quarters · filed 2020-03-26 | ||
| 2018-06-30 | $789.44K derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $1.04M derived: sum of 2 quarters · filed 2020-03-26 | $703.20K derived: sum of 3 quarters · filed 2020-03-26 | $708.90K 10-KT · filed 2020-03-26 | ||
| 2018-03-31 | $254.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | -$86.24K derived: sum of 2 quarters · filed 2018-05-14 | -$80.54K 10-Q · filed 2018-05-14 | -$184.12K derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-12-31 | -$341.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | -$335.40K 10-Q · filed 2018-02-12 | -$438.98K derived: sum of 3 quarters · filed 2018-11-13 | -$683.06K derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-09-30 | $5.70K 10-Q · filed 2018-11-13 | -$97.88K derived: sum of 2 quarters · filed 2018-11-13 | -$341.95K derived: sum of 3 quarters · filed 2018-11-13 | -$790.99K derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-06-30 | -$103.58K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-28 | -$347.65K derived: sum of 2 quarters · filed 2018-09-28 | -$796.69K derived: sum of 3 quarters · filed 2018-09-28 | -$716.65K 10-K · filed 2018-09-28 | ||
| 2017-03-31 | -$244.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | -$693.12K derived: sum of 2 quarters · filed 2018-05-14 | -$613.07K 10-Q · filed 2018-05-14 | -$334.65K derived: sum of 4 quarters · filed 2018-05-14 | ||
| 2016-12-31 | -$449.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-12 | -$369.00K 10-Q · filed 2018-02-12 | -$90.57K derived: sum of 3 quarters · filed 2018-02-12 | -$922.54K derived: sum of 4 quarters · filed 2018-02-12 | ||
| 2016-09-30 | $80.04K 10-Q · filed 2017-11-14 | $358.47K derived: sum of 2 quarters · filed 2017-11-14 | -$473.50K derived: sum of 3 quarters · filed 2017-11-14 | -$3.74M derived: sum of 4 quarters · filed 2017-11-14 | ||
| 2016-06-30 | $278.42K derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | -$553.55K derived: sum of 2 quarters · filed 2017-05-15 | -$3.82M derived: sum of 3 quarters · filed 2017-05-15 | -$13.11M 10-K · filed 2016-09-09 | ||
| 2016-03-31 | -$831.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | -$4.09M derived: sum of 2 quarters · filed 2017-05-15 | -$13.39M 10-Q · filed 2017-05-15 | -$23.85M derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | -$3.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-10 | -$12.56M 10-Q · filed 2017-02-10 | -$23.02M derived: sum of 3 quarters · filed 2017-02-10 | -$25.12M derived: sum of 4 quarters · filed 2017-02-10 | ||
| 2015-09-30 | -$9.29M 10-Q · filed 2016-11-10 | -$19.76M derived: sum of 2 quarters · filed 2016-11-10 | -$21.86M derived: sum of 3 quarters · filed 2016-11-10 | -$31.70M derived: sum of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | -$10.47M derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | -$12.57M derived: sum of 2 quarters · filed 2016-09-09 | -$22.40M derived: sum of 3 quarters · filed 2016-09-09 | $3.71M 10-K · filed 2016-09-09 | ||
| 2015-03-31 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-09 | -$11.94M derived: sum of 2 quarters · filed 2016-05-09 | $14.18M 10-Q · filed 2016-05-09 | $29.46M derived: sum of 4 quarters · filed 2016-05-09 | ||
| 2014-12-31 | -$9.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-05 | $16.28M 10-Q · filed 2016-02-05 | $31.56M derived: sum of 3 quarters · filed 2016-02-05 | $24.23M derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2014-09-30 | $26.11M 10-Q · filed 2015-11-06 | $41.40M derived: sum of 2 quarters · filed 2015-11-06 | $34.07M derived: sum of 3 quarters · filed 2015-11-06 | $34.07M derived: sum of 4 quarters · filed 2015-11-06 | ||
| 2014-06-30 | $15.28M derived: 10-K 6 month − 8-K 3 month · filed 2015-09-11 | $7.95M 10-K · filed 2015-09-11 | $7.95M derived: sum of 3 quarters · filed 2015-09-11 | $8.97M derived: sum of 4 quarters · filed 2015-09-11 | ||
| 2014-03-31 | -$7.33M 8-K · filed 2014-05-27 | -$7.33M derived: sum of 2 quarters · filed 2015-02-13 | -$6.31M 10-Q · filed 2015-05-15 | $9.24M 8-K · filed 2014-05-27 | ||
| 2013-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-13 | $1.02M 10-Q · filed 2015-02-13 | $12.88M 10-K · filed 2015-09-11 | $16.57M 8-K · filed 2014-05-27 | ||
| 2013-09-30 | $1.02M 10-Q · filed 2014-11-07 | |||||
| 2012-12-31 | $3.69M 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |